NCT06764316 - A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

July 30, 2030

Study Completion Date

December 31, 2033

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

BAY 3547926

antibody conjugate with actinium-225 label

DRUG

BAY 3547922

antibody conjugate without actinium-225 label as preinjection

Trial Locations (10)

2650

RECRUITING

UZA - Digestive Oncology, Edegem

8500

RECRUITING

az Groeninge - Digestive Oncology, Kortrijk

20540

RECRUITING

Turku University Hospital - Oncology Department, Turku

28050

RECRUITING

The START Center for Cancer Care - Madrid - CIOCC - Hospital Universitario Madrid Sanchinarro - Oncologia, Madrid

33520

RECRUITING

Tampere University Hospital, Cancer Center, Tampere

H2X 0A9

RECRUITING

Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopi, Montreal

H4A 3J1

RECRUITING

McGill University Health Centre (MUHC) - Research Institute (RI) - McConnell Centre for Innovative Medicine (CIM), Montreal

J1H 5N4

RECRUITING

CIUSSS de l'Estrie-CHUS, Sherbrooke

Surrey

RECRUITING

"Royal Marsden NHS Foundation Trust , Sutton - Gastrointestinal Unit"

Unknown

RECRUITING

"Imperial College Healthcare NHS Trust , Hammersmith Hospital - Garry Weston Centre"